Filing Flows › Tenaya Therapeutics (TNYA) › Q1 2026
Tenaya Therapeutics (TNYA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Tenaya Therapeutics (TNYA) reported revenue of $225K for the first quarter 2026 (Q1 2026).
Tenaya Therapeutics, Q1 2026: revenue $225K, net loss $19.3M, operating cash flow −$19.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $225K | — | — |
| Operating profit | −$20.1M | — | — |
| Net earnings | −$19.3M | — | — |
| Operating cash flow | −$19.2M | — | — |
What changed
Revenue was $225K in Q1 2026.
Operating costs exceeded revenue by $20.1M, an operating margin of -8917.8%. The quarter ended with a net loss of $19.3M.
Operating cash flow was −$19.2M. Non-cash charges added back $1.8M of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items used $3.9M. Capital expenditures of $11K exceeded it, leaving free cash flow of −$19.2M.
Questions
What was Tenaya Therapeutics' revenue in the first quarter 2026?
Tenaya Therapeutics (TNYA) reported revenue of $225K for the first quarter 2026 (Q1 2026).